OncoHost’s AI-Based proteomic profiling platform, PROphet, to serve key role in host response evaluation of late-stage disease patients
The acquisition supports Algorics' commitment to expanding its team of experienced analytical professionals and sustaining its commercial growth
The new Access AMH Advanced aims to provide validated cut-offs for the assessment of ovarian reserve and ovarian response as an aid for women undergoing in vitro fertilization (IVF)
Watch world-leading clinical scientists and healthcare professionals online, June 22-23, to discover the latest tools and techniques advancing COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more
New smartphone-sized test device uses innovative ‘lab on chip’ technology for rapid, accurate results
Collaboration follows successful acquisition and commercialization of Oxsed, an Oxford University Spin-out, to scale OxLAMP rapid COVID-19 test globally
Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%
The fast time-to-result includes a pretreatment process to inactivate the virus as a safeguard for laboratory staff handling the samples
The two patents protect opaganib and RHB-107 for the treatment of COVID-19 until at least 2041 once granted
Explore the latest science and technology advancements in regenerative medicine, COVID-19 diagnostic testing, cardiovascular treatments, point-of-care and more
The Simplexa™ SARS-CoV-2 Variants Direct assay aims to enable detection of four mutations associated with virus variants without requiring upfront RNA extraction
The availability of an International Standard (IS) for antibodies facilitates the standardization of SARS-CoV-2 serological methods
The independent study is being led by Southampton University Health Sciences
In a Phase 3 trial, the vaccine was 100% effective and generally well tolerated in participants aged 12 to 15 years
Vaccine, trialed in 450 children, shows favorable safety profile and was well-tolerated
COVID-19 infections fell by 65% percent after a first dose of the Oxford-AstraZeneca or Pfizer-BioNTech vaccines in this large community surveillance study
Sensor could be used in discovering new treatments for mental illness, in neuroscience research and to detect drugs of abuse
